Plus therapeutics reports fourth quarter and full year 2024 financial results and recent business highlights

Houston, march 27, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announces financial results for the fourth quarter and full year ended december 31, 2024, and provides an overview of recent and upcoming business highlights. “over the last twelve months, plus has reported very promising safety and efficacy data for our lead drug reyobiq administered in our two most advanced cns cancer programs,” said marc h.
pstv Ratings Summary
pstv Quant Ranking